[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 225
Citations 0
Comment & Response
December 2018

BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases

Author Affiliations
  • 1Unit of Medical Oncology 2, Azienda Ospedaliero, Universitaria Pisana, Pisa, Italy
  • 2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
JAMA Surg. 2018;153(12):1162-1163. doi:10.1001/jamasurg.2018.3334

To the Editor In their article, Margonis et al1 report the role of BRAF V600E mutation as the strongest determinant of prognosis in a large cohort of 849 patients with resected colorectal liver metastases (CRLM). Their findings are consistent with previous reports in the literature,2 including our retrospective series.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×